<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Heart Vessels</journal-id><journal-id journal-id-type="iso-abbrev">Heart Vessels</journal-id><journal-title-group><journal-title>Heart and Vessels</journal-title></journal-title-group><issn pub-type="ppub">0910-8327</issn><issn pub-type="epub">1615-2573</issn><publisher><publisher-name>Springer Japan</publisher-name><publisher-loc>Tokyo</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27469320</article-id><article-id pub-id-type="pmc">5334385</article-id><article-id pub-id-type="publisher-id">879</article-id><article-id pub-id-type="doi">10.1007/s00380-016-0879-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Risk factors associated with bleeding after multi antithrombotic therapy during implantation of cardiac implantable electronic devices</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ishibashi</surname><given-names>Kohei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Miyamoto</surname><given-names>Koji</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kamakura</surname><given-names>Tsukasa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wada</surname><given-names>Mitsuru</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nakajima</surname><given-names>Ikutaro</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Inoue</surname><given-names>Yuko</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Okamura</surname><given-names>Hideo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Noda</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Aiba</surname><given-names>Takeshi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kamakura</surname><given-names>Shiro</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shimizu</surname><given-names>Wataru</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yasuda</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Akasaka</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kusano</surname><given-names>Kengo</given-names></name><address><phone>+81-6-6833-5012</phone><email>kusanokengo@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0378 8307</institution-id><institution-id institution-id-type="GRID">grid.410796.d</institution-id><institution>Department of Cardiovascular Medicine, </institution><institution>National Cerebral and Cardiovascular Center, </institution></institution-wrap>5-7-1 Fujishiro-dai, Suita, Osaka 565-8565 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2173 8328</institution-id><institution-id institution-id-type="GRID">grid.410821.e</institution-id><institution>Department of Cardiovascular Medicine, </institution><institution>Nippon Medical School, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1763 1087</institution-id><institution-id institution-id-type="GRID">grid.412857.d</institution-id><institution>Department of Cardiovascular Medicine, </institution><institution>Wakayama Medical University, </institution></institution-wrap>Wakayama, Japan </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>32</volume><issue>3</issue><fpage>333</fpage><lpage>340</lpage><history><date date-type="received"><day>19</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p>Previous studies showed that continuous anticoagulation or single antiplatelet therapy during implantations of cardiac implantable electronic devices (CIED) was relatively safe. However, the safety of continuous multi antithrombotic therapy (AT) in patients undergoing CIED interventions has not been clearly defined. We sought to evaluate the safety of this therapy during CIED implantations. A total of 300 consecutive patients (mean 69&#x000a0;years old, 171 males) with CIED implantations were enrolled in this study. The patients were divided into 6 groups [No-AT, oral anticoagulant therapy (OAT), single antiplatelet therapy (SAPT), OAT and SAPT, dual antiplatelet therapy (DAPT), triple AT (TAT)], and the perioperative complications were evaluated. Clinically significant pocket hematomas (PH) were defined as PH needing surgical intervention, prolonged hospitalizations, interruption of AT, or blood product transfusions. There were 129, 89, 49, 20, 10, and 3 patients in No-AT, OAT, SAPT, OAT&#x000a0;+&#x000a0;SAPT, DAPT, and TAT groups, respectively. The occurrence of clinically significant PH and thromboembolism did not differ among 6 groups (<italic>p</italic>&#x000a0;=&#x000a0;0.145 and <italic>p</italic>&#x000a0;=&#x000a0;0.795, respectively). However, high HAS-BLED score and valvular heart disease (VHD) were associated with clinically significant PH (<italic>p</italic>&#x000a0;=&#x000a0;0.014 and <italic>p</italic>&#x000a0;=&#x000a0;0.015, respectively). Continuous multi AT may be tolerated, but patients with high HAS-BLED score or VHD would require a careful attention during CIED implantations.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cardiac surgery</kwd><kwd>Electrophysiology</kwd><kwd>Implanted cardiac defibrillators</kwd><kwd>Pacemakers</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Japan 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Current guidelines recommend that patients without a high thromboembolic risk should stop antithrombotic therapy (AT) because the implantation of cardiac implantable electronic devices (CIED) with the concomitant use of AT poses an increased risk of perioperative bleeding complications [<xref ref-type="bibr" rid="CR1">1</xref>], but the interruption of antiplatelet and anticoagulant drugs increases thromboembolic events [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. On the other hand, previous studies showed that continuous anticoagulation during CIED implantations was safe, and a previous report revealed that antiplatelet therapy should not be stopped before low-invasive surgeries because local hematomas are easy to control their bleeding [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. Thus, continuous AT during CIED implantations has been recommended recently. In previous reports, a considerable number of patients with multi (dual or triple) AT were included. However, the safety of continuous multi AT in patients undergoing CIED implantations has not been sufficiently evaluated [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. In this study, we sought to evaluate the safety of continuous multi AT during CIED implantations.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patient population</title><p>This study was a retrospective observational study. The study population consisted of consecutive patients who underwent CIED [pacemaker (PM), implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy (CRT)-pacemaker (CRT-P), or CRT-defibrillator (CRT-D)] implantations without heparin bridging therapy in 2012. All patients who underwent the device surgery continued AT through the procedure. All patients underwent procedures with the standard techniques for a pectoral subfascial pocket formation and transvenous lead placement by way of the subclavian vein using tined or screw-in leads. All right atrial and right ventricular leads were positioned in the right auricular appendage and right ventricular apex, respectively. The left ventricular leads were positioned in the lateral, posterolateral, or anterior cardiac vein. Written informed consent was obtained from each patient in this study to undergo a CIED implantation. The privacy of the patients was protected by the anonymization of all data.</p></sec><sec id="Sec4"><title>Study protocol</title><p>Three hundred patients were enrolled in this study. Patients were divided into 6 groups as follows; No-AT group: patients without any AT, OAT group: patients with oral anticoagulant therapy (OAT), SAPT group: patients with single antiplatelet therapy (SAPT), OAT&#x000a0;+&#x000a0;SAPT group: patients with OAT and SAPT, DAPT group: patients with dual antiplatelet therapy (DAPT), and TAT group: patients with triple antithrombotic therapy (TAT). They were evaluated for any perioperative complications (bleeding or thromboembolic events) occurring within 30&#x000a0;days of the surgery. Bleeding events included pocket hematomas (PH), clinically significant PH, cerebral bleeding, gastrointestinal bleeding, and cardiac tamponade. The definition of PH was bleeding not requiring additional intervention but requiring treatment with compress. Clinically significant PH were defined as bleeding requiring surgical intervention, prolongation of hospitalization, interruption of AT, and blood product transfusions. Thromboembolic events included strokes, transient ischemic attacks (TIAs), myocardial infarctions, pulmonary embolisms, and deep vein thrombosis. Furthermore, the predictors of clinically significant PH were evaluated.</p></sec><sec id="Sec5"><title>Patient data collection and perioperative risk evaluation</title><p>The patient characteristics, including the co-morbidities and medication history, and procedural details were collected at the time of the CIED implantation. The HAS-BLED [hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (&#x0003e;65&#x000a0;years), drugs/alcohol] score was used to assess the bleeding risk, and scored hypertension (HT), abnormal renal/liver function (1 point each), strokes, bleeding history or a predisposition to it, labile international normalized ratio, being elderly (&#x0003e;65&#x000a0;years), and drugs/alcohol use (1 point each) [<xref ref-type="bibr" rid="CR14">14</xref>]. If the HAS-BLED score was &#x02265;3, a patient was considered to have a considerable risk of bleeding [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. Every thromboembolic risk factor was evaluated and we assessed the thromboembolic risk using the CHADS2 and CHA2DS2-VASc scores [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. The CHADS2 score assigned 1 point each for congestive heart failure (CHF), HT, age &#x02265;75&#x000a0;years, and diabetes mellitus (DM), and 2 points for a history of a stroke or TIA [<xref ref-type="bibr" rid="CR14">14</xref>]. The CHA2DS2-VASc score assigned 1 point each for CHF, HT, age 65&#x02013;74&#x000a0;years, DM, vascular disease, a female sex; and 2 points for an age &#x02265;75&#x000a0;years, and a history of a stroke or TIA [<xref ref-type="bibr" rid="CR18">18</xref>]. If the CHA2DS2-VASc score was &#x02265;2, a patient was considered to have a considerable risk of a thromboembolism [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec6"><title>Statistical analysis</title><p>The statistical analyses were performed using JMP version 9 software (SAS Institute Inc., Tokyo, Japan). The results are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SD for continuous variables. Categorical data are presented as numbers (%). Differences among groups were analyzed by using the <italic>t-</italic>test for unpaired data, Chi-square test, and Fisher exact test, as appropriate. Differences in continuous variables were assessed using a one-way analysis of variance (ANOVA). A <italic>p</italic> value &#x0003c;0.05 was considered significant. Logistic regression analysis was used to estimate the magnitude of association [i.e., odds ratios (ORs)] between clinically significant PH and clinical characteristics.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Clinical characteristics of No-AT, OAT, SAPT, OAT&#x000a0;+&#x000a0;SAPT, DAPT and TAT groups</title><p>The baseline characteristics are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The number of patients in No-AT, OAT, SAPT, OAT&#x000a0;+&#x000a0;SAPT, DAPT, and TAT groups was 129, 89, 49, 20, 10 and 3, respectively. The mean patient age was 69&#x000a0;years; 171 (57&#x000a0;%) were male. The frequency of ischemic heart disease, valvular heart disease (VHD), and atrial fibrillation was 18, 8 and 27&#x000a0;%, respectively. The rate of anticoagulant drug use was 37&#x000a0;%, and a novel oral anticoagulant (NOAC) use was observed in only 5 patients in this study. The prothrombin time-international ratio (PT-INR) as a warfarin control parameter was 1.7 and there was no significant difference in the PT-INR among OAT, OAT&#x000a0;+&#x000a0;SAPT, and TAT groups. The rate of antiplatelet drug use was 32&#x000a0;%.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Comparison of the clinical characteristics among No-AT, OAT, SAPT, OAT&#x000a0;+&#x000a0;SAPT, DAPT, and TAT groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Total (<italic>n</italic>&#x000a0;=&#x000a0;300)</th><th align="left">No-AT (<italic>n</italic>&#x000a0;=&#x000a0;129)</th><th align="left">OAT (<italic>n</italic>&#x000a0;=&#x000a0;89)</th><th align="left">SAPT (<italic>n</italic>&#x000a0;=&#x000a0;49)</th><th align="left">OAT&#x000a0;+&#x000a0;SAPT (<italic>n</italic>&#x000a0;=&#x000a0;20)</th><th align="left">DAPT (<italic>n</italic>&#x000a0;=&#x000a0;10)</th><th align="left">TAT (<italic>n</italic>&#x000a0;=&#x000a0;3)</th><th align="left">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">69&#x000a0;&#x000b1;&#x000a0;16</td><td align="left">66&#x000a0;&#x000b1;&#x000a0;19</td><td align="left">69&#x000a0;&#x000b1;&#x000a0;14</td><td align="left">75&#x000a0;&#x000b1;&#x000a0;11</td><td align="left">72&#x000a0;&#x000b1;&#x000a0;10</td><td align="left">65&#x000a0;&#x000b1;&#x000a0;12</td><td align="left">64&#x000a0;&#x000b1;&#x000a0;21</td><td align="left">0.017</td></tr><tr><td align="left">Male</td><td align="left">171 (57)</td><td align="left">68 (53)</td><td align="left">41 (46)</td><td align="left">34 (69)</td><td align="left">15 (75)</td><td align="left">10 (100)</td><td align="left">3 (100)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Body height (cm)</td><td align="left">159&#x000a0;&#x000b1;&#x000a0;11</td><td align="left">159&#x000a0;&#x000b1;&#x000a0;11</td><td align="left">158&#x000a0;&#x000b1;&#x000a0;10</td><td align="left">159&#x000a0;&#x000b1;&#x000a0;8</td><td align="left">162&#x000a0;&#x000b1;&#x000a0;10</td><td align="left">167&#x000a0;&#x000b1;&#x000a0;10</td><td align="left">166&#x000a0;&#x000b1;&#x000a0;3</td><td align="left">0.155</td></tr><tr><td align="left">Body weight (kg)</td><td align="left">55&#x000a0;&#x000b1;&#x000a0;11</td><td align="left">55&#x000a0;&#x000b1;&#x000a0;11</td><td align="left">53&#x000a0;&#x000b1;&#x000a0;12</td><td align="left">56&#x000a0;&#x000b1;&#x000a0;10</td><td align="left">56&#x000a0;&#x000b1;&#x000a0;11</td><td align="left">62&#x000a0;&#x000b1;&#x000a0;9</td><td align="left">62&#x000a0;&#x000b1;&#x000a0;6</td><td align="left">0.101</td></tr><tr><td align="left">BMI</td><td align="left">22&#x000a0;&#x000b1;&#x000a0;3</td><td align="left">22&#x000a0;&#x000b1;&#x000a0;3</td><td align="left">21&#x000a0;&#x000b1;&#x000a0;4</td><td align="left">22&#x000a0;&#x000b1;&#x000a0;3</td><td align="left">21&#x000a0;&#x000b1;&#x000a0;4</td><td align="left">22&#x000a0;&#x000b1;&#x000a0;2</td><td align="left">23&#x000a0;&#x000b1;&#x000a0;3</td><td align="left">0.349</td></tr><tr><td align="left">Serum creatinine (mg/dl)</td><td align="left">1.1&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left">0.9&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="left">1.2&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="left">1.4&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="left">1.3&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="left">1.0&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left">1.1&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Blood hemoglobin (g/dl)</td><td align="left">12.7&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="left">13.0&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="left">12.6&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="left">12.6&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="left">12.5&#x000a0;&#x000b1;&#x000a0;2.2</td><td align="left">12.2&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="left">12.4&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="left">0.439</td></tr><tr><td align="left">Diabetes mellitus</td><td align="left">68 (23)</td><td align="left">16 (12)</td><td align="left">19 (21)</td><td align="left">18 (37)</td><td align="left">9 (45)</td><td align="left">5 (50)</td><td align="left">1 (33)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Hypertension</td><td align="left">147 (49)</td><td align="left">61 (47)</td><td align="left">32 (36)</td><td align="left">35 (71)</td><td align="left">11 (55)</td><td align="left">6 (60)</td><td align="left">2 (67)</td><td align="left">0.004</td></tr><tr><td align="left">Ischemic heart disease</td><td align="left">54 (18)</td><td align="left">3 (2)</td><td align="left">2 (2)</td><td align="left">26 (53)</td><td align="left">11 (55)</td><td align="left">9 (90)</td><td align="left">3 (100)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Valvular heart disease</td><td align="left">23 (8)</td><td align="left">2 (2)</td><td align="left">18 (20)</td><td align="left">1 (2)</td><td align="left">2 (10)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Atrial fibrillation</td><td align="left">82 (27)</td><td align="left">11 (9)</td><td align="left">52 (58)</td><td align="left">2 (4)</td><td align="left">15 (75)</td><td align="left">0 (0)</td><td align="left">2 (67)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left" colspan="9">Drug</td></tr><tr><td align="left" colspan="9">&#x000a0;Anticoagulant drug</td></tr><tr><td align="left">&#x000a0;&#x000a0;Warfarin</td><td align="left">107 (36)</td><td align="left">&#x02013;</td><td align="left">85 (96)</td><td align="left">&#x02013;</td><td align="left">19 (95)</td><td align="left">&#x02013;</td><td align="left">3 (100)</td><td align="left">&#x02013;</td></tr><tr><td align="left">&#x000a0;&#x000a0;Control of PT-INR</td><td align="left">1.7&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="left">&#x02013;</td><td align="left">1.7&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="left">&#x02013;</td><td align="left">1.8&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="left">&#x02013;</td><td align="left">1.4&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left">&#x02013;</td></tr><tr><td align="left">&#x000a0;&#x000a0;NOAC</td><td align="left">5 (1)</td><td align="left">&#x02013;</td><td align="left">4 (4)</td><td align="left">&#x02013;</td><td align="left">1 (5)</td><td align="left">&#x02013;</td><td align="left">0 (0)</td><td align="left">&#x02013;</td></tr><tr><td align="left" colspan="9">&#x000a0;Antiplatelet drug</td></tr><tr><td align="left">&#x000a0;&#x000a0;Aspirin</td><td align="left">74 (25)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">41 (84)</td><td align="left">20 (100)</td><td align="left">10 (100)</td><td align="left">3 (100)</td><td align="left">&#x02013;</td></tr><tr><td align="left">&#x000a0;&#x000a0;Thienopyridine</td><td align="left">13 (4)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">2 (4)</td><td align="left">0 (0)</td><td align="left">8 (80)</td><td align="left">3 (100)</td><td align="left">&#x02013;</td></tr><tr><td align="left">&#x000a0;&#x000a0;Cilostazol</td><td align="left">8 (3)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">6 (12)</td><td align="left">0 (0)</td><td align="left">2 (20)</td><td align="left">0 (0)</td><td align="left">&#x02013;</td></tr><tr><td align="left">&#x003b2;-Blocker</td><td align="left">138 (46)</td><td align="left">39 (30)</td><td align="left">55 (62)</td><td align="left">23 (47)</td><td align="left">13 (65)</td><td align="left">6 (60)</td><td align="left">2 (67)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">ACE inhibitor/ARB</td><td align="left">143 (48)</td><td align="left">45 (35)</td><td align="left">52 (58)</td><td align="left">27 (55)</td><td align="left">9 (45)</td><td align="left">7 (70)</td><td align="left">3 (100)</td><td align="left">0.002</td></tr><tr><td align="left">Statin</td><td align="left">101 (34)</td><td align="left">27 (21)</td><td align="left">25 (28)</td><td align="left">29 (59)</td><td align="left">10 (50)</td><td align="left">7 (70)</td><td align="left">3 (100)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Diuretics</td><td align="left">141 (47)</td><td align="left">32 (25)</td><td align="left">65 (73)</td><td align="left">24 (49)</td><td align="left">11 (55)</td><td align="left">6 (60)</td><td align="left">3 (100)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Amiodarone</td><td align="left">51 (17)</td><td align="left">10 (8)</td><td align="left">22 (25)</td><td align="left">10 (20)</td><td align="left">4 (20)</td><td align="left">3 (30)</td><td align="left">2 (67)</td><td align="left">0.002</td></tr></tbody></table><table-wrap-foot><p>Values are given as the <italic>n</italic> (%) or mean&#x000a0;&#x000b1;&#x000a0;standard deviation</p><p>
<italic>ACE</italic> angiotensin converting enzyme, <italic>ARB</italic> angiotensin receptor blocker, <italic>AT</italic> antithrombotic therapy, <italic>BMI</italic> body mass index, <italic>DAPT</italic> dual antiplatelet therapy, <italic>NOAC</italic> novel oral anticoagulant, <italic>OAT</italic> oral anticoagulant therapy, <italic>PT-INR</italic> prothrombin time-international ratio, <italic>SAPT</italic> single antiplatelet therapy, <italic>TAT</italic> triple antithrombotic therapy</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec9"><title>Procedural data of No-AT, OAT, SAPT, OAT&#x000a0;+&#x000a0;SAPT, DAPT and TAT groups</title><p>The frequency of a large device (ICD and CRT-D), de novo implantation, and system upgrade were 44, 63 and 3&#x000a0;%, respectively. The mean procedure time was 1.8&#x000a0;h. There were no significant differences among the 6 groups regarding the CRD type, rate of de novo implantations, system upgrades, or procedure time (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Comparison of the procedural data among No-AT, OAT, SAPT, OAT&#x000a0;+&#x000a0;SAPT, DAPT, and TAT groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Total (n&#x000a0;=&#x000a0;300)</th><th align="left">No-AT (<italic>n</italic>&#x000a0;=&#x000a0;129)</th><th align="left">OAT (<italic>n</italic>&#x000a0;=&#x000a0;89)</th><th align="left">SAPT (<italic>n</italic>&#x000a0;=&#x000a0;49)</th><th align="left">OAT&#x000a0;+&#x000a0;SAPT (<italic>n</italic>&#x000a0;=&#x000a0;20)</th><th align="left">DAPT (<italic>n</italic>&#x000a0;=&#x000a0;10)</th><th align="left">TAT (<italic>n</italic>&#x000a0;=&#x000a0;3)</th><th align="left">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="8">Type of CIED</td><td char="." align="char">0.522</td></tr><tr><td align="left">&#x000a0;PM and CRT-P</td><td align="left">167 (56)</td><td align="left">75 (58)</td><td align="left">52 (58)</td><td align="left">27 (55)</td><td align="left">8 (40)</td><td align="left">4 (40)</td><td align="left">1 (33)</td><td align="left"/></tr><tr><td align="left">&#x000a0;ICD and CRT-D</td><td align="left">133 (44)</td><td align="left">54 (42)</td><td align="left">37 (42)</td><td align="left">22 (45)</td><td align="left">12 (60)</td><td align="left">6 (60)</td><td align="left">2 (67)</td><td align="left"/></tr><tr><td align="left">De novo implantation</td><td align="left">190 (63)</td><td align="left">78 (60)</td><td align="left">54 (61)</td><td align="left">35 (71)</td><td align="left">13 (65)</td><td align="left">7 (70)</td><td align="left">3 (100)</td><td char="." align="char">0.540</td></tr><tr><td align="left">System upgrade</td><td align="left">10 (3)</td><td align="left">4 (3)</td><td align="left">3 (3)</td><td align="left">3 (6)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td char="." align="char">0.800</td></tr><tr><td align="left">Procedure time (h)</td><td align="left">1.8&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="left">1.8&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left">1.9&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="left">2.1&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="left">1.9&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left">1.7&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left">2.3&#x000a0;&#x000b1;&#x000a0;0.9</td><td char="." align="char">0.482</td></tr></tbody></table><table-wrap-foot><p>Values are given as the <italic>n</italic> (%) or mean&#x000a0;&#x000b1;&#x000a0;standard deviation</p><p>
<italic>AT</italic> antithrombotic therapy, <italic>CIED</italic> cardiac implantable electronic device, <italic>CRT-D</italic> cardiac resynchronization therapy-defibrillator, <italic>CRT-P</italic> cardiac resynchronization therapy-pacemaker, <italic>DAPT</italic> dual antiplatelet therapy, <italic>ICD</italic> implantable cardioverter-defibrillator, <italic>OAT</italic> oral anticoagulant therapy, <italic>PM</italic> pacemaker, <italic>SAPT</italic> single antiplatelet therapy, <italic>TAT</italic> triple antithrombotic therapy</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Bleeding and thromboembolic risk data of No-AT, OAT, SAPT, OAT&#x000a0;+&#x000a0;SAPT, DAPT, and TAT groups</title><p>The bleeding and thromboembolic risk data of the 6 groups is shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. The mean HAS-BLED score, CHADS<sub>2</sub> score, and CHA<sub>2</sub>DS<sub>2</sub>-VASc score was 1.2, 1.8, and 3.2, respectively. HAS-BLED score &#x02265;3 as a high bleeding risk parameter was 21 (7&#x000a0;%) and significant difference among the 6 groups. CHA2DS2-VASc score &#x02265;2 as a considerable thromboembolic risk parameter was 247 (82&#x000a0;%) and significant difference among the 6 groups.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Comparison of the bleeding and thromboembolic risk data among No-AT, OAT, SAPT, OAT&#x000a0;+&#x000a0;SAPT, DAPT, and TAT groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Total (<italic>n</italic>&#x000a0;=&#x000a0;300)</th><th align="left">No-AT (<italic>n</italic>&#x000a0;=&#x000a0;129)</th><th align="left">OAT (<italic>n</italic>&#x000a0;=&#x000a0;89)</th><th align="left">SAPT (<italic>n</italic>&#x000a0;=&#x000a0;49)</th><th align="left">OAT&#x000a0;+&#x000a0;SAPT (<italic>n</italic>&#x000a0;=&#x000a0;20)</th><th align="left">DAPT (<italic>n</italic>&#x000a0;=&#x000a0;10)</th><th align="left">TAT (<italic>n</italic>&#x000a0;=&#x000a0;3)</th><th align="left">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="9">Bleeding risk data</td></tr><tr><td align="left">&#x000a0;HAS-BLED score</td><td align="left">1.2&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="left">0.8&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left">1.0&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left">2.0&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="left">2.1&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="left">2.0&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="left">1.7&#x000a0;&#x000b1;&#x000a0;0.6</td><td char="." align="char">&#x0003c;0.001</td></tr><tr><td align="left">&#x000a0;HAS-BLED score &#x02265;3</td><td align="left">21 (7)</td><td align="left">2 (2)</td><td align="left">3 (3)</td><td align="left">10 (20)</td><td align="left">2 (10)</td><td align="left">4 (40)</td><td align="left">0 (0)</td><td char="." align="char">0.001</td></tr><tr><td align="left" colspan="9">Thromboembolic risk data</td></tr><tr><td align="left">&#x000a0;Prior stroke/recurrent venous thromboembolism</td><td align="left">34 (11)</td><td align="left">4 (3)</td><td align="left">14 (16)</td><td align="left">8 (16)</td><td align="left">7 (35)</td><td align="left">0 (0)</td><td align="left">1 (33)</td><td char="." align="char">&#x0003c;0.001</td></tr><tr><td align="left">&#x000a0;Active cancer</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">&#x02013;</td></tr><tr><td align="left">&#x000a0;Thrombophilia</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">&#x02013;</td></tr><tr><td align="left">&#x000a0;CHADS<sub>2</sub> score</td><td align="left">1.8&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="left">1.2&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="left">1.9&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="left">2.5&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="left">2.8&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="left">1.8&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="left">2.7&#x000a0;&#x000b1;&#x000a0;2.1</td><td char="." align="char">&#x0003c;0.001</td></tr><tr><td align="left">&#x000a0;CHA<sub>2</sub>DS<sub>2</sub>-VASc score</td><td align="left">3.2&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="left">2.5&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="left">3.3&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="left">4.3&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="left">4.7&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="left">3.4&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="left">4.3&#x000a0;&#x000b1;&#x000a0;2.5</td><td char="." align="char">&#x0003c;0.001</td></tr><tr><td align="left">&#x000a0;CHA<sub>2</sub>DS<sub>2</sub>-VASc score &#x02265;2</td><td align="left">247 (82)</td><td align="left">88 (68)</td><td align="left">80 (90)</td><td align="left">47 (96)</td><td align="left">19 (95)</td><td align="left">10 (100)</td><td align="left">3 (100)</td><td char="." align="char">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>Values are given as the <italic>n</italic> (%) or mean&#x000a0;&#x000b1;&#x000a0;standard deviation</p><p>
<italic>AT</italic> antithrombotic therapy, <italic>DAPT</italic> dual antiplatelet therapy, <italic>OAT</italic> oral anticoagulant therapy, <italic>SAPT</italic> single antiplatelet therapy, <italic>TAT</italic> triple antithrombotic therapy</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>Perioperative complication data of No-AT, OAT, SAPT, OAT&#x000a0;+&#x000a0;SAPT, DAPT, and TAT groups</title><p>PH and clinically significant PH occurred 17 (6&#x000a0;%) and 9 (3&#x000a0;%) patients, respectively. The frequency of PH was significantly different, but the frequency of clinically significant PH was not different among the 6 groups (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The gastrointestinal bleeding occurred 2 (1&#x000a0;%) and there was no significant difference among the 6 groups (<italic>p</italic>&#x000a0;=&#x000a0;0.113). No subjects had any cardiac tamponade and cerebral bleeding.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>
<bold>a</bold> Pocket hematoma and clinically significant pocket hematoma among No-AT, OAT, SAPT, OAT&#x000a0;+&#x000a0;SAPT, DAPT, and TAT groups. The frequency of PH was 3, 7, 4, 25, 0 and 0&#x000a0;% in No-AT, OAT, SAPT, OAT&#x000a0;+&#x000a0;SAPT, DAPT and TAT groups, respectively, and was significantly different among the 6 groups. <bold>b</bold> The frequency of clinically significant PH was 1, 6, 2, 10, 0 and 0&#x000a0;% in No-AT, OAT, SAPT, OAT&#x000a0;+&#x000a0;SAPT, DAPT and TAT groups, respectively, and was not different among the 6 groups. <italic>AT</italic> antithrombotic therapy, <italic>DAPT</italic> dual antiplatelet therapy, <italic>OAT</italic> oral anticoagulant therapy, <italic>PH</italic> pocket hematoma, <italic>SAPT</italic> single antiplatelet therapy, <italic>TAT</italic> triple antithrombotic therapy</p></caption><graphic xlink:href="380_2016_879_Fig1_HTML" id="MO1"/></fig>
</p><p>Thromboembolic event occurred in only one patient and there was no significant difference in the frequency of that event among the 6 groups (<italic>p</italic>&#x000a0;=&#x000a0;0.795).</p></sec><sec id="Sec12"><title>Predictors of clinically significant PH</title><p>The frequency of VHD [OR 6.8; 95&#x000a0;% confidence interval (CI) 1.4&#x02013;27.8; <italic>p</italic>&#x000a0;=&#x000a0;0.010] or high HAS-BLED score (OR 2.2; 95&#x000a0;% CI 1.1&#x02013;4.3; <italic>p</italic>&#x000a0;=&#x000a0;0.021) were major predictors of clinically significant PH by univariate analysis, as shown in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. In addition, low body mass index (OR 0.78; 95&#x000a0;% CI 0.6&#x02013;0.98; <italic>p</italic>&#x000a0;=&#x000a0;0.040) was also a significant predictor of clinically significant PH by univariate analysis. The frequency of VHD (OR 7.2; 95&#x000a0;% CI 1.3&#x02013;35.0; <italic>p</italic>&#x000a0;=&#x000a0;0.015) or high HAS-BLED score (OR 2.5; 95&#x000a0;% CI 1.2&#x02013;5.3; <italic>p</italic>&#x000a0;=&#x000a0;0.014) remained significant independent predictors of clinically significant PH developing by multivariate analysis.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Univariate and multivariate analyses of predictors of clinically significant PH</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="3">Univariate analysis</th><th align="left" colspan="3">Multivariate analysis</th></tr><tr><th align="left">Odds ratio</th><th align="left">
<italic>p</italic> value</th><th align="left">95&#x000a0;% CI</th><th align="left">Odds ratio</th><th align="left">
<italic>p</italic> value</th><th align="left">95&#x000a0;% CI</th></tr></thead><tbody><tr><td align="left">Male gender</td><td char="." align="char">2.71</td><td char="." align="char">0.219</td><td char="&#x02013;" align="char">0.64&#x02013;18.40</td><td align="left"/><td align="left"/><td char="&#x02013;" align="char"/></tr><tr><td align="left">Age (years)</td><td char="." align="char">1.05</td><td char="." align="char">0.126</td><td char="&#x02013;" align="char">0.99&#x02013;1.12</td><td align="left"/><td align="left"/><td char="&#x02013;" align="char"/></tr><tr><td align="left">BMI</td><td char="." align="char">0.78</td><td char="." align="char">0.040</td><td char="&#x02013;" align="char">0.61&#x02013;0.98</td><td char="." align="char">0.79</td><td char="." align="char">0.076</td><td char="&#x02013;" align="char">0.61&#x02013;1.01</td></tr><tr><td align="left">Valvular heart disease</td><td char="." align="char">6.77</td><td char="." align="char">0.010</td><td char="&#x02013;" align="char">1.35&#x02013;27.79</td><td char="." align="char">7.18</td><td char="." align="char">0.015</td><td char="&#x02013;" align="char">1.31&#x02013;34.98</td></tr><tr><td align="left">Ischemic heart disease</td><td char="." align="char">1.31</td><td char="." align="char">0.739</td><td char="&#x02013;" align="char">0.19&#x02013;5.62</td><td align="left"/><td align="left"/><td char="&#x02013;" align="char"/></tr><tr><td align="left">CHADS2 score</td><td char="." align="char">1.28</td><td char="." align="char">0.317</td><td char="&#x02013;" align="char">0.77&#x02013;2.04</td><td align="left"/><td align="left"/><td char="&#x02013;" align="char"/></tr><tr><td align="left">HAS-BLED score</td><td char="." align="char">2.20</td><td char="." align="char">0.021</td><td char="&#x02013;" align="char">1.11&#x02013;4.33</td><td char="." align="char">2.50</td><td char="." align="char">0.014</td><td char="&#x02013;" align="char">1.20&#x02013;5.34</td></tr><tr><td align="left">High joule device</td><td char="." align="char">1.59</td><td char="." align="char">0.495</td><td char="&#x02013;" align="char">0.41&#x02013;6.54</td><td align="left"/><td align="left"/><td char="&#x02013;" align="char"/></tr><tr><td align="left">Generator exchange</td><td char="." align="char">2.21</td><td char="." align="char">0.244</td><td char="&#x02013;" align="char">0.57&#x02013;9.11</td><td align="left"/><td align="left"/><td char="&#x02013;" align="char"/></tr><tr><td align="left">Operation time (h)</td><td char="." align="char">1.50</td><td char="." align="char">0.140</td><td char="&#x02013;" align="char">0.81&#x02013;2.47</td><td align="left"/><td align="left"/><td char="&#x02013;" align="char"/></tr><tr><td align="left">Blood hemoglobin (g/dl)</td><td char="." align="char">0.85</td><td char="." align="char">0.387</td><td char="&#x02013;" align="char">0.57&#x02013;1.23</td><td align="left"/><td align="left"/><td char="&#x02013;" align="char"/></tr><tr><td align="left">Serum creatinine (mg/dl)</td><td char="." align="char">1.19</td><td char="." align="char">0.624</td><td char="&#x02013;" align="char">0.42&#x02013;2.03</td><td align="left"/><td align="left"/><td char="&#x02013;" align="char"/></tr></tbody></table><table-wrap-foot><p>
<italic>BMI</italic> body mass index, <italic>CI</italic> confidence interval</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec13"><title>Discussion</title><p>To the best of our knowledge, this is the first report on the comprehensive data concerning the safety of continuous multi AT during CIED implantations. The results of this study revealed that continuous multi AT was acceptable but high HAS-BLED and VHD were independent predictors of clinically significant PH during CIED implantations. These findings suggested that continuous multi AT may be tolerated, but patients with high HAS-BLED score or VHD would require a careful attention during CIED implantations.</p><p>Although the rate of clinically significant PH did not differ significantly among the 6 groups in our study, 5&#x000a0;% of that complication rate in AT was relatively high. Previous studies revealed that a perioperative continuous single AT was associated with an incidence of PH of 1.9&#x02013;6.6&#x000a0;% [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. Thus, the clinically significant PH rate of the multi AT in our study may be acceptable.</p><p>The incidence of thromboembolic events was rare and did not differ significantly among the 6 groups in this study. The thromboembolic event rate of the single AT was 0&#x02013;1&#x000a0;% in previous studies [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. Continuous multi AT may be effective in suppressing thromboembolic events within the perioperative period.</p><p>High HAS-BLED score and VHD were independent predictors of clinically significant PH during CIED implantations in this study. There is no report revealing that VHD is associated with bleeding complication during CIED implantations; however, one previous study said that the observed risk of bleeding was higher with AT in patients with VHD compared with patients without VHD [<xref ref-type="bibr" rid="CR28">28</xref>]. Since VHD is a considerable disease, specific attention is needed in this population during CIED implantations.</p><p>There were many warfarin users in our study, so our results are acceptable for patients with warfarin. The mean PT-INR of the warfarin users in this study was 1.7 and it was a low control level considering the previous data [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The bleeding risk in Asians is greater than that of the people in the other countries [<xref ref-type="bibr" rid="CR31">31</xref>]. Previous Japanese registries revealed that a PT-INR of 1.6&#x02013;2.6 was safe and effective in preventing thromboembolic events, particularly in patients aged &#x02265;70&#x000a0;years old [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>]. The recommended PT-INR in the Japanese guidelines is 2.0&#x02013;3.0 and 1.6&#x02013;2.6 for patients aged &#x0003c;70&#x000a0;years and &#x02265;70&#x000a0;years, respectively [<xref ref-type="bibr" rid="CR33">33</xref>]. Thus, our control level of the PT-INR was acceptable. In contrast, only 1&#x000a0;% of the patients used NOACs, so we could not sufficiently evaluate the safety and efficacy of NOACs. Previous studies revealed that continuous NOAC use was safe during CIED implantations [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Thus, multi AT including NOACs may be safe and effective.</p></sec><sec id="Sec14"><title>Limitations</title><p>There are several limitations to our study. The patient number in this study, especially for NOAC users, was very small. The evaluation of large number in this topic is needed by a future study. Furthermore, procedures performed by experienced operators carry a lower risk of clinically significant PH compared with trainees and less experienced operators [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Our hospital is a high-volume center (mean operation procedures, 500 per year) for CIED implantations, and experienced operators performed all surgeries in our study. A future multi-center study is needed to resolve this problem.</p></sec><sec id="Sec15"><title>Conclusions</title><p>Continuous multi AT may be tolerated, but patients with high HAS-BLED score or VHD would require a careful attention during CIED implantations.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACE</term><def><p>Angiotensin converting enzyme</p></def></def-item><def-item><term>ANOVA</term><def><p>Analysis of variance</p></def></def-item><def-item><term>ARB</term><def><p>Angiotensin receptor blocker</p></def></def-item><def-item><term>AT</term><def><p>Antithrombotic therapy</p></def></def-item><def-item><term>BMI</term><def><p>Body mass index</p></def></def-item><def-item><term>CHF</term><def><p>Congestive heart failure</p></def></def-item><def-item><term>CI</term><def><p>Confidence interval</p></def></def-item><def-item><term>CIED</term><def><p>Cardiac implantable electronic device</p></def></def-item><def-item><term>CRT</term><def><p>Cardiac resynchronization therapy</p></def></def-item><def-item><term>CRT-D</term><def><p>Cardiac resynchronization therapy-defibrillator</p></def></def-item><def-item><term>CRT-P</term><def><p>Cardiac resynchronization therapy-pacemaker</p></def></def-item><def-item><term>DAPT</term><def><p>Dual antiplatelet therapy</p></def></def-item><def-item><term>DM</term><def><p>Diabetes mellitus</p></def></def-item><def-item><term>HT</term><def><p>Hypertension</p></def></def-item><def-item><term>ICD</term><def><p>Implantable cardioverter defibrillator</p></def></def-item><def-item><term>OAT</term><def><p>Oral anticoagulant therapy</p></def></def-item><def-item><term>NOAC</term><def><p>Novel oral anticoagulant</p></def></def-item><def-item><term>PH</term><def><p>Pocket hematoma</p></def></def-item><def-item><term>PM</term><def><p>Pacemaker</p></def></def-item><def-item><term>PT-INR</term><def><p>Prothrombin time-international ratio</p></def></def-item><def-item><term>SAPT</term><def><p>Single antiplatelet therapy</p></def></def-item><def-item><term>SD</term><def><p>Standard deviation</p></def></def-item><def-item><term>TAT</term><def><p>Triple antithrombotic therapy</p></def></def-item><def-item><term>TIA</term><def><p>Transient ischemic attack</p></def></def-item><def-item><term>VHD</term><def><p>Valvular heart disease</p></def></def-item></def-list></glossary><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Sources of funding</title><p>None.</p></sec><sec id="FPar2"><title>Conflict of interest</title><p>All authors, do not have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this article.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daubert</surname><given-names>JC</given-names></name><name><surname>Saxon</surname><given-names>L</given-names></name><name><surname>Adamson</surname><given-names>PB</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name><name><surname>Berger</surname><given-names>RD</given-names></name><name><surname>Beshai</surname><given-names>JF</given-names></name><name><surname>Breithard</surname><given-names>O</given-names></name><name><surname>Brignole</surname><given-names>M</given-names></name><name><surname>Cleland</surname><given-names>J</given-names></name><name><surname>Delurgio</surname><given-names>DB</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Exner</surname><given-names>DV</given-names></name><name><surname>Gold</surname><given-names>M</given-names></name><name><surname>Grimm</surname><given-names>RA</given-names></name><name><surname>Hayes</surname><given-names>DL</given-names></name><name><surname>Israel</surname><given-names>C</given-names></name><name><surname>Leclercq</surname><given-names>C</given-names></name><name><surname>Linde</surname><given-names>C</given-names></name><name><surname>Lindenfeld</surname><given-names>J</given-names></name><name><surname>Merkely</surname><given-names>B</given-names></name><name><surname>Mont</surname><given-names>L</given-names></name><name><surname>Murgatroyd</surname><given-names>F</given-names></name><name><surname>Prinzen</surname><given-names>F</given-names></name><name><surname>Saba</surname><given-names>SF</given-names></name><name><surname>Shinbane</surname><given-names>JS</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>AS</given-names></name><name><surname>Vardas</surname><given-names>PE</given-names></name><name><surname>Wilkoff</surname><given-names>BL</given-names></name><name><surname>Zamorano</surname><given-names>JL</given-names></name></person-group><article-title>2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management</article-title><source>Heart Rhythm</source><year>2012</year><volume>9</volume><fpage>1524</fpage><lpage>1576</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2012.07.025</pub-id><pub-id pub-id-type="pmid">22939223</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Aronow</surname><given-names>HD</given-names></name></person-group><article-title>Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy</article-title><source>Mayo Clin Proc</source><year>2006</year><volume>81</volume><fpage>641</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.4065/81.5.641</pub-id><pub-id pub-id-type="pmid">16706262</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popma</surname><given-names>JJ</given-names></name><name><surname>Berger</surname><given-names>P</given-names></name><name><surname>Ohman</surname><given-names>EM</given-names></name><name><surname>Harrington</surname><given-names>RA</given-names></name><name><surname>Grines</surname><given-names>C</given-names></name><name><surname>Weitz</surname><given-names>JI</given-names></name></person-group><article-title>Antithrombotic therapy during percutaneous coronary intervention: the seventh ACCP conference on antithrombotic and thrombolytic therapy</article-title><source>Chest</source><year>2004</year><volume>126</volume><fpage>576s</fpage><lpage>599s</lpage><pub-id pub-id-type="doi">10.1378/chest.126.3_suppl.576S</pub-id><pub-id pub-id-type="pmid">15383485</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>SY</given-names></name><name><surname>Kang</surname><given-names>WC</given-names></name><name><surname>Oh</surname><given-names>PC</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Moon</surname><given-names>CI</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>SH</given-names></name><name><surname>Ahn</surname><given-names>T</given-names></name><name><surname>Choi</surname><given-names>IS</given-names></name><name><surname>Shin</surname><given-names>EK</given-names></name></person-group><article-title>Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation</article-title><source>Heart Vessels</source><year>2014</year><volume>29</volume><fpage>578</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1007/s00380-013-0399-x</pub-id><pub-id pub-id-type="pmid">23974943</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamatani</surname><given-names>Y</given-names></name><name><surname>Iguchi</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Ohtani</surname><given-names>R</given-names></name><name><surname>Yamashita</surname><given-names>Y</given-names></name><name><surname>Takagi</surname><given-names>D</given-names></name><name><surname>Unoki</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>M</given-names></name><name><surname>Masunaga</surname><given-names>N</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Hamatani</surname><given-names>M</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Akao</surname><given-names>M</given-names></name></person-group><article-title>Incidence and predictors of ischemic stroke during hospitalization for congestive heart failure</article-title><source>Heart Vessels</source><year>2015</year></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birnie</surname><given-names>DH</given-names></name><name><surname>Healey</surname><given-names>JS</given-names></name><name><surname>Wells</surname><given-names>GA</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>AS</given-names></name><name><surname>Krahn</surname><given-names>AD</given-names></name><name><surname>Simpson</surname><given-names>CS</given-names></name><name><surname>Ayala-Paredes</surname><given-names>F</given-names></name><name><surname>Coutu</surname><given-names>B</given-names></name><name><surname>Leiria</surname><given-names>TL</given-names></name><name><surname>Essebag</surname><given-names>V</given-names></name></person-group><article-title>Pacemaker or defibrillator surgery without interruption of anticoagulation</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><fpage>2084</fpage><lpage>2093</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1302946</pub-id><pub-id pub-id-type="pmid">23659733</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>CP</given-names></name><name><surname>Bernard</surname><given-names>ML</given-names></name><name><surname>Brabham</surname><given-names>WW</given-names></name><name><surname>Netzler</surname><given-names>PC</given-names></name><name><surname>Sidney</surname><given-names>DS</given-names></name><name><surname>Cuoco</surname><given-names>F</given-names></name><name><surname>Sturdivant</surname><given-names>JL</given-names></name><name><surname>Leman</surname><given-names>RB</given-names></name><name><surname>Wharton</surname><given-names>JM</given-names></name><name><surname>Gold</surname><given-names>MR</given-names></name></person-group><article-title>Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices</article-title><source>Am J Cardiol</source><year>2013</year><volume>111</volume><fpage>1165</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2012.12.046</pub-id><pub-id pub-id-type="pmid">23360767</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosiuk</surname><given-names>J</given-names></name><name><surname>Koutalas</surname><given-names>E</given-names></name><name><surname>Doering</surname><given-names>M</given-names></name><name><surname>Sommer</surname><given-names>P</given-names></name><name><surname>Rolf</surname><given-names>S</given-names></name><name><surname>Breithardt</surname><given-names>OA</given-names></name><name><surname>Nedios</surname><given-names>S</given-names></name><name><surname>Dinov</surname><given-names>B</given-names></name><name><surname>Hindricks</surname><given-names>G</given-names></name><name><surname>Richter</surname><given-names>S</given-names></name><name><surname>Bollmann</surname><given-names>A</given-names></name></person-group><article-title>Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations</article-title><source>Europace</source><year>2014</year><volume>16</volume><fpage>1028</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1093/europace/eut423</pub-id><pub-id pub-id-type="pmid">24489073</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosiuk</surname><given-names>J</given-names></name><name><surname>Koutalas</surname><given-names>E</given-names></name><name><surname>Doering</surname><given-names>M</given-names></name><name><surname>Nedios</surname><given-names>S</given-names></name><name><surname>Sommer</surname><given-names>P</given-names></name><name><surname>Rolf</surname><given-names>S</given-names></name><name><surname>Darma</surname><given-names>A</given-names></name><name><surname>Breithardt</surname><given-names>OA</given-names></name><name><surname>Dinov</surname><given-names>B</given-names></name><name><surname>Hindricks</surname><given-names>G</given-names></name><name><surname>Richter</surname><given-names>S</given-names></name><name><surname>Bollmann</surname><given-names>A</given-names></name></person-group><article-title>Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case&#x02013;control study</article-title><source>. Circ J</source><year>2014</year><volume>78</volume><fpage>2402</fpage><lpage>2407</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-14-0665</pub-id><pub-id pub-id-type="pmid">25253506</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zac&#x000e0;</surname><given-names>V</given-names></name><name><surname>Marcucci</surname><given-names>R</given-names></name><name><surname>Parodi</surname><given-names>G</given-names></name><name><surname>Limbruno</surname><given-names>U</given-names></name><name><surname>Notarstefano</surname><given-names>P</given-names></name><name><surname>Pieragnoli</surname><given-names>P</given-names></name><name><surname>Di Cori</surname><given-names>A</given-names></name><name><surname>Bongiorni</surname><given-names>MG</given-names></name><name><surname>Casolo</surname><given-names>G</given-names></name></person-group><article-title>Management of antithrombotic therapy in patients undergoing electrophysiological device surgery</article-title><source>Europace</source><year>2015</year><volume>17</volume><fpage>840</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1093/europace/euu357</pub-id><pub-id pub-id-type="pmid">25712980</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sticherling</surname><given-names>C</given-names></name><name><surname>Marin</surname><given-names>F</given-names></name><name><surname>Birnie</surname><given-names>D</given-names></name><name><surname>Boriani</surname><given-names>G</given-names></name><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Dan</surname><given-names>GA</given-names></name><name><surname>Gulizia</surname><given-names>M</given-names></name><name><surname>Halvorsen</surname><given-names>S</given-names></name><name><surname>Hindricks</surname><given-names>G</given-names></name><name><surname>Kuck</surname><given-names>KH</given-names></name><name><surname>Moya</surname><given-names>A</given-names></name><name><surname>Potpara</surname><given-names>T</given-names></name><name><surname>Roldan</surname><given-names>V</given-names></name><name><surname>Tilz</surname><given-names>R</given-names></name><name><surname>Lip</surname><given-names>GYH</given-names></name></person-group><article-title>Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS)</article-title><source>Europace</source><year>2015</year><volume>17</volume><fpage>1197</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1093/europace/euv190</pub-id><pub-id pub-id-type="pmid">26105732</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lip</surname><given-names>GYH</given-names></name><name><surname>Windecker</surname><given-names>S</given-names></name><name><surname>Huber</surname><given-names>K</given-names></name><name><surname>Kirchhof</surname><given-names>P</given-names></name><name><surname>Marin</surname><given-names>F</given-names></name><name><surname>TenBerg</surname><given-names>JM</given-names></name><name><surname>Haeusler</surname><given-names>KG</given-names></name><name><surname>Boriani</surname><given-names>G</given-names></name><name><surname>Capodanno</surname><given-names>D</given-names></name><name><surname>Gilard</surname><given-names>M</given-names></name><name><surname>Zeymer</surname><given-names>U</given-names></name><name><surname>Lane</surname><given-names>D</given-names></name></person-group><article-title>Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><fpage>3155</fpage><lpage>3179</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehu298</pub-id><pub-id pub-id-type="pmid">25154388</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name></person-group><article-title>The safety and efficacy of antithrombotic therapy in patients undergoing cardiac rhythm device implantation: a meta-analysis</article-title><source>Europace</source><year>2015</year><volume>17</volume><fpage>1076</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1093/europace/euu369</pub-id><pub-id pub-id-type="pmid">25713013</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gage</surname><given-names>BF</given-names></name><name><surname>Waterman</surname><given-names>AD</given-names></name><name><surname>Shannon</surname><given-names>W</given-names></name><name><surname>Boechler</surname><given-names>M</given-names></name><name><surname>Rich</surname><given-names>MW</given-names></name><name><surname>Radford</surname><given-names>MJ</given-names></name></person-group><article-title>Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation</article-title><source>JAMA</source><year>2001</year><volume>285</volume><fpage>2864</fpage><lpage>2870</lpage><pub-id pub-id-type="doi">10.1001/jama.285.22.2864</pub-id><pub-id pub-id-type="pmid">11401607</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camm</surname><given-names>AJ</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>Savelieva</surname><given-names>I</given-names></name><name><surname>Atar</surname><given-names>D</given-names></name><name><surname>Hohnloser</surname><given-names>SH</given-names></name><name><surname>Hindricks</surname><given-names>G</given-names></name><name><surname>Kirchhof</surname><given-names>P</given-names></name></person-group><article-title>2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><fpage>2719</fpage><lpage>2747</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehs253</pub-id><pub-id pub-id-type="pmid">22922413</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>Frison</surname><given-names>L</given-names></name><name><surname>Halperin</surname><given-names>JL</given-names></name><name><surname>Lane</surname><given-names>DA</given-names></name></person-group><article-title>Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>57</volume><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2010.09.024</pub-id><pub-id pub-id-type="pmid">21111555</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>DA</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation</article-title><source>Circulation</source><year>2012</year><volume>126</volume><fpage>860</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.060061</pub-id><pub-id pub-id-type="pmid">22891166</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>Nieuwlaat</surname><given-names>R</given-names></name><name><surname>Pisters</surname><given-names>R</given-names></name><name><surname>Lane</surname><given-names>DA</given-names></name><name><surname>Crijns</surname><given-names>HJ</given-names></name></person-group><article-title>Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation</article-title><source>Chest</source><year>2010</year><volume>137</volume><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1378/chest.09-1584</pub-id><pub-id pub-id-type="pmid">19762550</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douketis</surname><given-names>JD</given-names></name><name><surname>Spyropoulos</surname><given-names>AC</given-names></name><name><surname>Spencer</surname><given-names>FA</given-names></name><name><surname>Mayr</surname><given-names>M</given-names></name><name><surname>Jaffer</surname><given-names>AK</given-names></name><name><surname>Eckman</surname><given-names>MH</given-names></name><name><surname>Dunn</surname><given-names>AS</given-names></name><name><surname>Kunz</surname><given-names>R</given-names></name><collab>American Collegeof Chest Physicians</collab></person-group><article-title>Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</article-title><source>Chest</source><year>2012</year><volume>141</volume><fpage>e326S</fpage><lpage>e350S</lpage><pub-id pub-id-type="doi">10.1378/chest.11-2298</pub-id><pub-id pub-id-type="pmid">22315266</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamula</surname><given-names>E</given-names></name><name><surname>Douketis</surname><given-names>JD</given-names></name><name><surname>Schulman</surname><given-names>S</given-names></name></person-group><article-title>Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide</article-title><source>J Thromb Haemost</source><year>2008</year><volume>6</volume><fpage>1615</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2008.03080.x</pub-id><pub-id pub-id-type="pmid">18638011</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Khadra</surname><given-names>AS</given-names></name></person-group><article-title>Implantation of pacemakers and implantable cardioverter defibrillators in orally anticoagulated patients</article-title><source>Pacing Clin Electrophysiol</source><year>2003</year><volume>26</volume><fpage>511</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1046/j.1460-9592.2003.00084.x</pub-id><pub-id pub-id-type="pmid">12687880</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giudici</surname><given-names>MC</given-names></name><name><surname>Paul</surname><given-names>DL</given-names></name><name><surname>Bontu</surname><given-names>P</given-names></name><name><surname>Barold</surname><given-names>SS</given-names></name></person-group><article-title>Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy</article-title><source>Pacing Clin Electrophysiol</source><year>2004</year><volume>27</volume><fpage>358</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8159.2004.00441.x</pub-id><pub-id pub-id-type="pmid">15009863</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>DJ</given-names></name><name><surname>Losquadro</surname><given-names>W</given-names></name><name><surname>Spotnitz</surname><given-names>HM</given-names></name></person-group><article-title>Outpatient pacemaker procedures in orally anticoagulated patients</article-title><source>Pacing Clin Electrophysiol</source><year>1998</year><volume>21</volume><fpage>1730</fpage><lpage>1734</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8159.1998.tb00271.x</pub-id><pub-id pub-id-type="pmid">9744435</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tompkins</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Dalal</surname><given-names>D</given-names></name><name><surname>Brinker</surname><given-names>JA</given-names></name><name><surname>Leng</surname><given-names>CT</given-names></name><name><surname>Marine</surname><given-names>JE</given-names></name><name><surname>Nazarian</surname><given-names>S</given-names></name><name><surname>Spragg</surname><given-names>DD</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Halperin</surname><given-names>H</given-names></name><name><surname>Tomaselli</surname><given-names>GF</given-names></name><name><surname>Berger</surname><given-names>RD</given-names></name><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Henrikson</surname><given-names>CA</given-names></name></person-group><article-title>Dual antiplatelet therapy and heparin &#x0201c;bridging&#x0201d; significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>55</volume><fpage>2376</fpage><lpage>2382</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2009.12.056</pub-id><pub-id pub-id-type="pmid">20488310</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korantzopoulos</surname><given-names>P</given-names></name><name><surname>Letsas</surname><given-names>KP</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Fragakis</surname><given-names>N</given-names></name><name><surname>Efremidis</surname><given-names>M</given-names></name><name><surname>Goudevenos</surname><given-names>JA</given-names></name></person-group><article-title>Anticoagulation and antiplatelet therapy in implantation of electrophysiological devices</article-title><source>Europace</source><year>2011</year><volume>13</volume><fpage>1669</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1093/europace/eur210</pub-id><pub-id pub-id-type="pmid">21788280</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiegand</surname><given-names>UK</given-names></name><name><surname>LeJeune</surname><given-names>D</given-names></name><name><surname>Boguschewski</surname><given-names>F</given-names></name><name><surname>Bonnemeier</surname><given-names>H</given-names></name><name><surname>Eberhardt</surname><given-names>F</given-names></name><name><surname>Schunkert</surname><given-names>H</given-names></name><name><surname>Bode</surname><given-names>F</given-names></name></person-group><article-title>Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy</article-title><source>Chest</source><year>2004</year><volume>126</volume><fpage>1177</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1378/chest.126.4.1177</pub-id><pub-id pub-id-type="pmid">15486380</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klug</surname><given-names>D</given-names></name><name><surname>Balde</surname><given-names>M</given-names></name><name><surname>Pavin</surname><given-names>D</given-names></name><name><surname>Hidden-Lucet</surname><given-names>F</given-names></name><name><surname>Clementy</surname><given-names>J</given-names></name><name><surname>Sadoul</surname><given-names>N</given-names></name><name><surname>Rey</surname><given-names>JL</given-names></name><name><surname>Lande</surname><given-names>G</given-names></name><name><surname>Lazarus</surname><given-names>A</given-names></name><name><surname>Victor</surname><given-names>J</given-names></name><name><surname>Barnay</surname><given-names>C</given-names></name><name><surname>Grandbastien</surname><given-names>B</given-names></name><name><surname>Kacet</surname><given-names>S</given-names></name></person-group><article-title>Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study</article-title><source>Circulation</source><year>2007</year><volume>116</volume><fpage>1349</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.678664</pub-id><pub-id pub-id-type="pmid">17724263</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breithardt</surname><given-names>G</given-names></name><name><surname>Baumgartner</surname><given-names>H</given-names></name><name><surname>Berkowitz</surname><given-names>SD</given-names></name><name><surname>Hellkamp</surname><given-names>AS</given-names></name><name><surname>Piccini</surname><given-names>JP</given-names></name><name><surname>Stevens</surname><given-names>SR</given-names></name><name><surname>Lokhnygina</surname><given-names>Y</given-names></name><name><surname>Patel</surname><given-names>MR</given-names></name><name><surname>Halperin</surname><given-names>JL</given-names></name><name><surname>Singer</surname><given-names>DE</given-names></name><name><surname>Hankey</surname><given-names>GJ</given-names></name><name><surname>Hacke</surname><given-names>W</given-names></name><name><surname>Becker</surname><given-names>RC</given-names></name><name><surname>Nessel</surname><given-names>CC</given-names></name><name><surname>Mahaffey</surname><given-names>KW</given-names></name><name><surname>Fox</surname><given-names>KA</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><collab>ROCKETAF Steering Committee Investigators</collab></person-group><article-title>Clinical characteristics and outcome with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><fpage>3377</fpage><lpage>3385</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehu305</pub-id><pub-id pub-id-type="pmid">25148838</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>RG</given-names></name><name><surname>Sherman</surname><given-names>DG</given-names></name><name><surname>Easton</surname><given-names>JD</given-names></name><name><surname>Cairns</surname><given-names>JA</given-names></name></person-group><article-title>Prevention of stroke in patients with nonvalvular atrial fibrillation</article-title><source>Neurology</source><year>1998</year><volume>51</volume><fpage>674</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1212/WNL.51.3.674</pub-id><pub-id pub-id-type="pmid">9748009</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hylek</surname><given-names>EM</given-names></name><name><surname>Skates</surname><given-names>SJ</given-names></name><name><surname>Sheehan</surname><given-names>MA</given-names></name><name><surname>Singer</surname><given-names>DE</given-names></name></person-group><article-title>An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation</article-title><source>N Engl J Med</source><year>1996</year><volume>335</volume><fpage>540</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1056/NEJM199608223350802</pub-id><pub-id pub-id-type="pmid">8678931</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>AY</given-names></name><name><surname>Yao</surname><given-names>JF</given-names></name><name><surname>Brar</surname><given-names>SS</given-names></name><name><surname>Jorgensen</surname><given-names>MB</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>50</volume><fpage>309</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2007.01.098</pub-id><pub-id pub-id-type="pmid">17659197</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasaka</surname><given-names>M</given-names></name><name><surname>Minematsu</surname><given-names>K</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name></person-group><article-title>Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation</article-title><source>Intern Med</source><year>2001</year><volume>40</volume><fpage>1183</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.40.1183</pub-id><pub-id pub-id-type="pmid">11813841</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Atarashi</surname><given-names>H</given-names></name><name><surname>Kamakura</surname><given-names>S</given-names></name><name><surname>Koretsune</surname><given-names>Y</given-names></name><name><surname>Kumagai</surname><given-names>K</given-names></name><name><surname>Mitamura</surname><given-names>H</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Sugi</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Yasaka</surname><given-names>M</given-names></name><name><surname>Satomi</surname><given-names>K</given-names></name><name><surname>Kodama</surname><given-names>I</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name><name><surname>Ohe</surname><given-names>T</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name></person-group><article-title>Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013)</article-title><source>Circ J</source><year>2014</year><volume>78</volume><fpage>1997</fpage><lpage>2021</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-66-0092</pub-id><pub-id pub-id-type="pmid">24965079</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>JCS Joint Working Group</collab></person-group><article-title>Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry</article-title><source>Circ J</source><year>2013</year><volume>77</volume><fpage>2264</fpage><lpage>2270</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-13-0290</pub-id><pub-id pub-id-type="pmid">23708863</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tolosana</surname><given-names>JM</given-names></name><name><surname>Berne</surname><given-names>P</given-names></name><name><surname>Mont</surname><given-names>L</given-names></name><name><surname>Heras</surname><given-names>M</given-names></name><name><surname>Berruezo</surname><given-names>A</given-names></name><name><surname>Monteagudo</surname><given-names>J</given-names></name><name><surname>Tamborero</surname><given-names>D</given-names></name><name><surname>Benito</surname><given-names>B</given-names></name><name><surname>Brugada</surname><given-names>J</given-names></name></person-group><article-title>Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial</article-title><source>Eur Heart J</source><year>2009</year><volume>30</volume><fpage>1880</fpage><lpage>1884</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehp194</pub-id><pub-id pub-id-type="pmid">19487235</pub-id></element-citation></ref></ref-list></back></article>